RBC Capital Maintains Outperform on DexCom, Lowers Price Target to $115
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Shagun Singh maintains an Outperform rating on DexCom (NASDAQ:DXCM) but lowers the price target from $120 to $115.
October 25, 2024 | 5:19 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital has maintained its Outperform rating on DexCom but has lowered the price target from $120 to $115, indicating a slight decrease in expected future performance.
The Outperform rating suggests continued confidence in DexCom's performance, but the lowered price target indicates a tempered outlook. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100